retatrutide when will it be available Retatrutide: FDA approval time, trial results & weight loss 🎙️ NEW EPISODE: Retatrutide—The Triple

These benefits were further supported by the results of the SUMMIT trial, which investigated tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, in patients with HFpEF with or without T2D

Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity

Therefore, we have transferred the evidence on NAFLD to the MASLD population and use the term MASLD interchangeably

As of April 2026, retatrutide is not approved by the FDA, is not approved by the EMA, and has no active approval in any major regulatory jurisdiction

Keep track of your progress regularly and work with healthcare professionals to fine-tune your approach for the best outcomes and reduced muscle loss